On March 11, 2024 Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, reported that it will present its next generation ADC platform IDDC and the latest study results of multiple novel ADCs (9MW2821, 7MW3711, 9MW2921) developed based on this platform as poster presentation at the 14th World ADC London from March 12-15, 2024 local time (Press release, Mabwell Biotech, MAR 11, 2024, View Source [SID1234641028]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The World ADC Event Series is the largest academic event in the global ADC field.
Poster Presentation
Poster Title: Mtoxin Payload Applied in IDDC ADC Platform Significant Increases Therapeutic Index and Overcome MultiDrug Resistance in Various Tumor
Booth No.: 26
About the next generation ADC platform IDDC
IDDC is a next generation ADC site-specific conjugation technology platform independently developed by Mabwell, consisting of multiple systematic core patented technologies including the site-specific conjugation process DARfinity, the site-specific linker IDconnect, the novel payload Mtoxin, and the conditional release structure LysOnly. The next generation ADCs developed based on the above systematic patented technologies have better structural uniformity, quality stability, efficacy, and tolerability.
The IDDC platform has already been validated in multiple drugs under study. It is anticipated that more ADCs based on this platform will enter the clinical development stage in the future.
9MW2821 – novel Nectin-4-targeting ADC:
Mabwell is the first Chinese enterprise to advance 9MW2821 into Phase 3 clinical trials for the treatment of urothelial carcinoma, making it the second globally in terms of progress; 9MW2821 is also the first therapeutic drug in the world with the same target to disclose clinical efficacy data for indications of cervical cancer and esophageal carcinoma.
7MW3711 – novel B7-H3-targeting ADC:
Clinical trials have been conducted for 7MW3711 for the indication of advanced solid tumors in China and it has received FDA approval to conduct clinical trials for patients with advanced malignant solid tumors.
9MW2921 – novel Trop-2-targeting ADC:
Clinical trials have been conducted for 9MW2921 for the indication of advanced solid tumors in China.